We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · July 26, 2021

Oxaliplatin Benefit in Stage III Colon Cancer According to IDEA Risk Groups

Clinical Colorectal Cancer


Additional Info

Clinical Colorectal Cancer
Benefit of Oxaliplatin in Stage III Colon Cancer According to IDEA Risk Groups: Findings From the ACCENT Database of 4934 Patients
Clin Colorectal Cancer 2021 Jun 01;20(2)130-136, O Margalit, B Boursi, M Rakez, A Thierry, G Yothers, N Wolmark, DG Haller, HJ Schmoll, Q Shi, E Shacham-Shmueli, A de Gramont

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading